TL;DR
A randomized, placebo-controlled trial presented at the American College of Rheumatology meeting found that 54.3% of patients with active systemic lupus erythematosus responded to daily sirolimus at 24 weeks, compared with 22.7% receiving placebo. The results suggest potential as an oral second-line option, but adverse effects and limited follow-up leave important safety and treatment-duration questions open.
A 145-patient randomized trial found that adults with systemic lupus erythematosus (SLE) that remained active despite standard treatment were more likely to improve after 24 weeks of daily sirolimus than after placebo. At the American College of Rheumatology’s annual meeting in Orlando, Liying Peng of Peking Union Medical Hospital reported response rates of 54.3% with sirolimus and 22.7% with placebo; the findings support further study, but do not settle whether the drug’s risks are acceptable for routine or long-term use.
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The trial assigned participants to 1.5 milligrams of sirolimus daily or placebo for 24 weeks, while both groups continued standard medications. The primary measure, SRI-4, requires a reduction of at least four points on a lupus disease activity scale, improvement in a physician assessment, and no specified worsening in organ involvement. The response difference was 31.6 percentage points, with a 95% confidence interval of 16.6 to 46.7.
Other reported measures also favored sirolimus. At 24 weeks, BICLA responses were 60% versus 31%. Average SLEDAI-2K scores fell by 4.7 points in the sirolimus group and 1.0 point with placebo, and the presenters reported improvement in biomarkers including anti-double-stranded DNA antibody levels. More demanding targets were less commonly reached: 14% achieved clinical remission and 24% reached low lupus disease activity state.
Safety findings were mixed. Among the 70 patients assigned sirolimus, investigators recorded two serious infections, and four stopped treatment because of adverse events. Menstrual irregularity was reported in 14% of the sirolimus group and none of the placebo group. Common adverse effects included laboratory changes: elevated triglycerides in 50%, elevated cholesterol in 37%, leukopenia in 27% and neutropenia in 21%. One participant died in each group; the deaths were considered unrelated to treatment, according to the report.
A Possible Oral Option for Refractory Lupus
The results may matter to people whose lupus remains active despite standard medicines and to clinicians seeking additional treatment choices. Sirolimus is an oral tablet, and the report noted that biologic drugs can face cost and access barriers, including insurance authorization requirements in the United States. The trial’s response rates were described as similar to those often seen with biologic lupus treatments, though that comparison does not establish that sirolimus is equivalent to any particular biologic.
Potential convenience must be weighed against the drug’s broad immunosuppressive effects and the trial’s adverse-event findings. The 24-week data show a short-term response signal, not proof that the medicine is safe for prolonged use or appropriate for every patient with lupus. The findings also do not establish that patients who respond would need to take sirolimus indefinitely.
Products Worth Considering

Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor

Garmin Forerunner 55 GPS Running Watch, Black

Philips Sonicare DiamondClean 9300 Electric Toothbrush, 2 Brush Heads, Black
As an affiliate, we earn on qualifying purchases.
From Early Study to Controlled Trial
Sirolimus had been studied previously in refractory SLE. A 2018 report in The Lancet described a single-arm study of 43 patients; among the 29 who completed a year of treatment, SLEDAI-2K scores fell by 50%, with no major safety issues reported in that group. Because that earlier study was unblinded and had no control group, it could not provide the same comparison as a placebo-controlled trial.
The new trial enrolled patients with a SLEDAI-2K score of at least 4 despite at least 12 weeks of standard antimalarial or immunosuppressive treatment. Participants had an average age of about 35, more than 90% were women, and disease duration averaged about nine years. People with substantial kidney impairment, certain other autoimmune diseases, or recent use of stronger immunosuppression such as intravenous cyclophosphamide were excluded. Those limits matter when applying the findings to patients who were not represented.
““Cost and access remain barriers” to the use of biologic lupus treatments.”
— Liying Peng, Peking Union Medical Hospital
Longer-Term Risks Still Need Study
The study lasted 24 weeks, too briefly to establish how safety and effectiveness may change with extended treatment. The report raised the possibility that some laboratory abnormalities could lead to clinical problems over time, but that possibility has not been confirmed by these trial results. An open-label extension is ongoing and may add follow-up information.
The available account does not provide all details needed to judge the findings independently, including a full breakdown of adverse events by severity and participant characteristics. The trial also excluded some patients with serious kidney impairment or recent potent immunosuppressive treatment. It remains unclear how well the results apply to those groups, whether benefits persist after treatment stops, and which patients are most likely to benefit.
Extension Phase to Track Outcomes
The reported next step is the 24-week open-label extension, which is expected to provide additional information about tolerability and outcomes with longer exposure. Because participants and investigators know treatment is being given in an open-label phase, its findings will not offer the same controlled comparison as the randomized portion.
For now, the trial supports further evaluation rather than a settled recommendation for routine use. Clinicians and patients will need fuller published results and longer follow-up to weigh response against infection risk, blood-count and lipid changes, and individual disease features. The report does not specify a regulatory decision or a timeline for one.
Key Questions
What did the sirolimus lupus trial find?
At 24 weeks, 54.3% of patients assigned sirolimus met the SRI-4 response measure, compared with 22.7% assigned placebo. The trial included 145 people with active SLE despite standard treatment.
Does the trial show that sirolimus is safe for long-term lupus treatment?
No. The randomized trial reported 24 weeks of follow-up. An open-label extension is ongoing, and longer-term risks and benefits remain uncertain.
What adverse effects were reported?
Reported findings included laboratory abnormalities such as elevated triglycerides and cholesterol, leukopenia and neutropenia. Two serious infections occurred among 70 patients assigned sirolimus, and four stopped it because of adverse events.
Did sirolimus put most patients into remission?
No. Although more than half met the trial’s SRI-4 response measure, 14% reached clinical remission and 24% reached low lupus disease activity state at 24 weeks. These are stricter outcomes than the primary response measure.
Can patients replace their current lupus medicines with sirolimus?
The trial does not establish that. Participants continued standard medications during the study, and the results do not provide instructions for changing or stopping prescribed treatment. Patients should discuss treatment decisions with their health care team.
Source: medpagetoday.com
